Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of “Hold” from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been assigned an average recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.00.

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Zacks Research lowered shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th.

Insider Buying and Selling

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock in a transaction on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the sale, the chief executive officer owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. This trade represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 113,693 shares of company stock worth $233,347. Company insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Simplify Asset Management Inc. raised its position in Milestone Pharmaceuticals by 186.2% in the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after buying an additional 1,842,974 shares during the last quarter. Propel Bio Management LLC boosted its holdings in shares of Milestone Pharmaceuticals by 186.1% during the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after acquiring an additional 3,333,333 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals in the third quarter worth approximately $1,333,000. Eaton Financial Holdings Company LLC purchased a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $26,000. Finally, SG Americas Securities LLC purchased a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $197,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.04 on Monday. Milestone Pharmaceuticals has a twelve month low of $0.63 and a twelve month high of $3.06. The company has a quick ratio of 7.96, a current ratio of 8.01 and a debt-to-equity ratio of 1.37. The firm has a market cap of $122.38 million, a PE ratio of -1.32 and a beta of 0.48. The business has a 50 day moving average of $1.72 and a 200 day moving average of $1.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its earnings results on Friday, March 20th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $37.52 million. On average, research analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.